Approximately 20–35% of melanoma and non-adenocarcinoma lung tumor cell lines had a reduced IFN-γ sensitivity, while ~10% of lung adenocarcinoma cell lines were resistant to IFN-γ treatment. Here, IFNG is linked to adenocarcinoma.